• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tetra Bio Pharma Inc (TSX: TBP )

    N/A UNCHANGED
    Last Price Updated: 3:59 PM EST, Mar 6, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Tetra Bio Pharma Inc

    Tetra Bio-Pharma Receives Funding from the Government of Canada for ARDS-003
    The Company is receiving up to $150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the development of its novel oral... 
    Via TheNewswire.com
    Exposures COVID-19
    Tetra Bio-Pharma Inc. Announces a Delay in Filing 2022 Annual Financial Statements and Related Management's Discussion and Analysis
    MONTREAL, QUEBEC – TheNewswire – March 1, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTC-PINK: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and... 
    Via TheNewswire.com
    The Power Play by The Market Herald Releases New Interviews with Group Eleven, iMining, Gamelancer, Cassiar Gold, ApartmentLove, Tetra Bio-Pharma and Sitka Gold Discussing Their Latest News
    Via ACCESSWIRE
    Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug
    From Akanda Corp. and Tetra Bio-Pharma
    Via Business Wire
    Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021
    LOS ANGELES, CA / ACCESSWIRE / December 6, 2021 / The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will... 
    From Stock News Now
    Via AccessWire
    Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting
    This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 28, 2021 to its short form base shelf prospectus dated April 1, 2020 - The... 
    From Tetra Bio-Pharma
    Via AccessWire
    Topics Cannabis Intellectual Property
    Exposures Cannabis Intellectual Property Product Safety
    Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain
    First ever clinical trial using pharmaceutical grade cannabis medication for use in managing uncontrolled cancer pain due to advanced cancer QIXLEEF™ has the potential to transform the pain market... 
    From Tetra Bio-Pharma
    Via AccessWire
    Topics Cannabis Intellectual Property
    Exposures Cannabis Intellectual Property Product Safety
    Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial
    First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment QIXLEEF™ has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 6, 2021 /... 
    From Tetra Bio-Pharma
    Via AccessWire
    Topics Cannabis Intellectual Property
    Exposures Cannabis Intellectual Property Product Safety
    Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios
    This Definitive Agreement is expected to generate an excess of $47,5M CAD in revenue for Tetra OTTAWA, ON / ACCESSWIRE / May 5, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company")... 
    From Tetra Bio-Pharma
    Via AccessWire
    Topics Cannabis Intellectual Property
    Exposures Cannabis Intellectual Property Product Safety
    Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals
    A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting OTTAWA, ON / ACCESSWIRE / May 4, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)... 
    From Tetra Bio-Pharma
    Via AccessWire
    Topics Cannabis Intellectual Property
    Exposures COVID-19 Cannabis Intellectual Property
    Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada
    The addressable market in Canada is estimated to be $80M CDN by 2022. Tetra also applies for a Health Canada Cannabis Drug License OTTAWA, ON / ACCESSWIRE / May 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra"... 
    From Tetra Bio-Pharma
    Via AccessWire
    Topics Cannabis Intellectual Property
    Exposures Cannabis Intellectual Property Product Safety
    Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority
    Tetra plans for global commercialization of QIXLEEF OTTAWA, ON / ACCESSWIRE / April 28, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in... 
    From Tetra Bio-Pharma
    Via AccessWire
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial
    - First clinical study to assess cannabis as an alternative to morphine - Tetra completes manufacturing of QIXLEEF clinical trial drug for REBORN1 trial - Export permit received from Health Canada for... 
    From Tetra Bio-Pharma
    Via AccessWire
    Topics Cannabis Intellectual Property
    Exposures Cannabis Intellectual Property Product Safety
    Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis
    - Tetra strengthens its intellectual property portfolio - Approximately 12% of women may have early symptoms of Interstitial Cystitis OTTAWA, ON / ACCESSWIRE / April 15, 2021 / Tetra Bio-Pharma Inc.... 
    From Tetra Bio-Pharma
    Via AccessWire
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada
    - REDUVO would have Canada's only Drug Identification Number for a THC-based prescription drug - The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / ACCESSWIRE / April 14, 2021 /... 
    From Tetra Bio-Pharma
    Via AccessWire
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.